Freenome (NASDAQ:FRNM) Stock Now Rated “Moderate Buy” by Wall Street Analysts

Shares of Freenome (NASDAQ:FRNM) have been assigned a consensus recommendation of “Moderate Buy” from the six ratings firms that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $18.00.

Several equities analysts recently issued reports on the stock. TD Cowen started coverage on shares of Freenome in a research report on Tuesday, August 18th. They set a “buy” rating and a $17.00 target price on the stock. Weiss Ratings assumed coverage on Freenome in a report on Monday, August 24th. They issued a “sell (d+)” rating for the company. BTIG Research started coverage on Freenome in a research note on Monday, August 17th. They set a “buy” rating and a $17.00 price target on the stock. Wall Street Zen upgraded Freenome to a “sell” rating in a report on Saturday. Finally, Guggenheim assumed coverage on Freenome in a research report on Thursday, August 20th. They issued a “buy” rating and a $21.00 price objective for the company.

Freenome Price Performance

Shares of FRNM stock opened at $15.99 on Friday. The stock has a market capitalization of $1.72 billion, a P/E ratio of -266.46 and a beta of 0.48. Freenome has a twelve month low of $9.97 and a twelve month high of $17.50.

About Freenome

Freenome is a biotechnology company developing blood-based tests designed to detect cancer at earlier, more treatable stages. Its approach combines artificial intelligence with multiomics analysis, examining biological signals in blood, including circulating tumor material and other molecular indicators.

The company has focused on noninvasive screening tests for colorectal cancer and other cancers. Freenome’s products remain in development and are being evaluated through clinical research and validation studies; the company’s tests are not described here as broadly approved diagnostic products.

Founded in 2014 and headquartered in the United States, Freenome has worked with healthcare providers, research organizations and pharmaceutical companies to advance its screening technology.